Wang Kun, Zhang Xi, Zhao Yang, Li Lifeng, Zhao Ruijie
Department of Neurology, Xingtai Central Hospital, Xingtai, Hebei Province, China.
Department of Neurology, Xingtai People's Hospital, Hebei Medical University Affiliated Hospital, Xingtai, Hebei Province, China.
Brain Behav. 2025 May;15(5):e70530. doi: 10.1002/brb3.70530.
We seek to investigate the efficacy of safflower yellow pigment in mitigating cerebral ischemia-reperfusion injury by examining its effects on protein nitration and oxidative modification.
A total of 160 patients with acute ischemic stroke admitted to the department of neurology of Xingtai people's hospital were included in this study. This study was a retrospective study. Patients were divided into the control group (n = 80) and the observation group (n = 80) according to whether safflower yellow pigment was used. The control group received conventional treatment, and the observation group received safflower yellow pigment.
Baseline characteristics did not significantly differ between the two groups (p > 0.05). Serum nitrosine levels were lower in the observation group compared to the control group after 24 h and one week of treatment (p < 0.05). Similarly, serum carbonylated protein levels were lower in the observation group after 24 h and one week of treatment (p < 0.05). The observation group exhibited lower NIHSS and modified rankin scale (mRS) scores, reduced cerebral ischemic area. Furthermore, levels of malondialdehyde (MDA), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) were lower, while superoxide dismutase (SOD) activity was higher in the observation group compared to the control group after one week of treatment (p < 0.05).
Safflower yellow pigment demonstrates significant neuroprotective effects in patients with cerebral ischemia-reperfusion injury by reducing protein oxidation and nitration, improving neurological function, reducing cerebral ischemic area, and attenuating oxidative stress and inflammation.
通过研究红花黄色素对蛋白质硝化和氧化修饰的影响,探讨其减轻脑缺血再灌注损伤的疗效。
本研究纳入了邢台市人民医院神经内科收治的160例急性缺血性脑卒中患者。本研究为回顾性研究。根据是否使用红花黄色素将患者分为对照组(n = 80)和观察组(n = 80)。对照组接受常规治疗,观察组接受红花黄色素治疗。
两组基线特征无显著差异(p > 0.05)。治疗24小时和1周后,观察组血清亚硝酸盐水平低于对照组(p < 0.05)。同样,治疗24小时和1周后,观察组血清羰基化蛋白水平较低(p < 0.05)。观察组美国国立卫生研究院卒中量表(NIHSS)和改良Rankin量表(mRS)评分较低,脑缺血面积减小。此外,治疗1周后,观察组丙二醛(MDA)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平较低,而超氧化物歧化酶(SOD)活性较高(p < 0.05)。
红花黄色素通过减少蛋白质氧化和硝化、改善神经功能、减小脑缺血面积以及减轻氧化应激和炎症,对脑缺血再灌注损伤患者具有显著的神经保护作用。